Previous Recommendation: Neutral
|
|
- Maria Edwards
- 5 years ago
- Views:
Transcription
1 2QFY11 Results Update SECTOR: PHARMACEUTICALS STOCK INFO. BSE Sensex: 20,589 S&P CNX: 6,194 BLOOMBERG JOL IN REUTERS CODE JUBO.BO Equity Shares (m) Week Range 413/255 1,6,12 Rel. Perf. (%) -4/-34/-8 M.Cap. (Rs b) 53.2 M.Cap. (US$ b) November 2010 Previous Recommendation: Neutral Neutral Rs313 2QFY11 performance was below estimates. Key highlights. Topline grew by 5.7%YoY to Rs9.88b (vs estimate of Rs10.49b), while Adjusted PAT increased by 42.3%YoY on a low base (impacted due to Rs428m of forex losses) to Rs821m (vs estimates of Rs948m). Overall, the Pharma and Life Sciences Products and Services (PLSPS) business reported revenue growth of 2.7%YoY to Rs8.5b while Agri & Performance Polymers (APP) business recorded 29%YoY growth to Rs1.38b. EBITDA declined by 16.3%YoY at Rs1.55b and was below our estimate of Rs1.96b. EBITDA margins at 15.7% (down 410bps) were lower than estimate of 18.7% due to pricing pressure and adverse currency movement and adverse product mix in PLSPS segment. Adjusted PAT increased by 42.3%YoY to Rs821m (vs estimate of Rs948m). Adjusted PAT reported growth despite decline in EBITDA on account of low base (impacted due to Rs428m of forex losses) and lower interest outgo due to reduction in debt. We believe Jubilant is well positioned to exploit the expected increase in outsourcing from India. Customer inventory destocking for CRAMS companies is coming to an end and we expect growth to rebound in FY11 as customers are likely to commence re-stocking. Over the past few years, Jubilant has made two large acquisitions in North America which has strengthened its presence in the sterile segment but has also resulted in a highly leveraged balance sheet. We also believe that some of the past acquisitions (like Draxis) have been made at expensive valuations resulting in extended payback periods. High debt, large FCCB redemption (US$202m in May-2011 including YTM) and low RoCE (8-12%) remain an overhang. Based on our revised estimates the stock is valued at 15.4x FY11E EPS and 12.8x FY12E EPS. Maintain Neutral. Nimish Desai (NimishDesai@MotilalOswal.com); Tel: / Amit Shah (Amit.Shah@MotilalOswal.com)
2 Performance was impacted by muted growth in PLSPS business Jubilant's 2QFY11 performance was below estimates. Topline grew by 5.7%YoY to Rs9.88b (vs estimate of Rs10.49b), EBITDA declined by 16.3%YoY to Rs1.55b (vs estimate of Rs1.96b) while Adjusted PAT increased by 42.3%YoY on a low base (impacted due to Rs428m of forex losses) to Rs821m (vs estimates of Rs948m). Overall, the Pharma and Life Sciences Products and Services (PLSPS) business reported revenue growth of 2.7%YoY to Rs8.5b (contributed 86% of revenues). The performance was impacted by 1) Flat revenues in Proprietary Product and Exclusive Synthesis segment at Rs2.45b due to lower prices. 2) A 1%YoY decline in Specialty Pharmaceutical business (Radiopharmaceuticals and Allergenic Extracts) to Rs605m due to low availability of Isotopes 3) Muted growth of 3% in CMO of sterile and non Sterile Products segment to Rs1.39b primarily due to delay in orders from clients and delay in getting products approvals at customer's end, 4) Flat revenues in Life Science Chemicals segment at Rs1.61b and 5) 19%YoY fall in the revenues from Drug Discovery and Development Services to Rs510m. On the positive side, the Generic dosage form and API business reported YoY growth of 50% and 11% respectively growth led by strong demand. Agri & Performance Polymers (APP) business recorded 29%YoY growth to Rs1.38b on the back of 98%YoY growth in Agri Products business to Rs690m led by increased capacity and nutrition based subsidy for fertilizers. Performance Polymers business reported 4%YoY decline to Rs690m due to lower utilization on account of product rationalization and debottlenecking of capacity in solid PVA. Sales mix (Rs m) 2QFY11 2QFY10 % YoY 1QFY11 % QoQ Prop. Products & Excl Synthesis 2,450 2, , Generic APIs CMO 1,390 1, ,400 (0.7) Contract Research (19.0) 540 (5.6) Total CRAMS 5,260 5, , Specialty Pharmaceuticals (0.8) Generic Formulations Total Pharma Sales 1, Life Science Chemicals 1,610 1, ,760 (8.5) Nutrition Ingredients Healthcare Total PLSPS Sales 8,500 8, , Total APP Sales 1,380 1, ,690 (18.3) Total Revenues 9,880 9, , Source: Company 11 November
3 EBITDA declined by 16.3%YoY at Rs1.55b below our estimates EBITDA declined by 16.3%YoY at Rs1.55b and was below our estimate of Rs1.96b. EBITDA margins at 15.7% (down 410bps) were lower than estimate of 18.7% due to pricing pressure and adverse currency movement and adverse product mix in PLSPS segment. EBITDA Margin Trend EBITDA (Rs m) Margin (%) ,622 1,851 2,251 2,163 1,567 1,549 1Q 2Q 3Q 4Q 1Q 2Q FY10 FY11 Source: Company PAT below estimate due to muted operational performance Adjusted PAT increased by 42.3%YoY to Rs821m (vs estimate of Rs948m). Adjusted PAT reported growth despite decline in EBITDA on account of low base (impacted due to Rs428m of forex losses) and lower interest outgo due to reduction in debt. De-merger of non-pharma (APP) business; Long-term +ve due to focus on Pharma business The management has approved de-merger of the APP business as part of its restructuring exercise. The de-merger will take place by the end of Nov As a first step, SML (JOL's 100% subsidiary) will be merged into JOL. A third-party contract manufacturer (PMSL) will also be merged into JOL. SML is engaged in the manufacturing of pyridine-based chemicals used in the Pharma & Agrochem industries. PMSL is an exclusive contract manufacturer for adhesives for JOL's consumer business. JOL will issue 501,364 shares to existing owners of PMSL as consideration for acquiring the business. At JOL's current market price, PMSL has been valued at Rs190m. In the second phase, JOL's APP business will be de-merged into a separate company to be known as Jubilant Industries (JIL) which will be listed separately (expected by Jan-11). Existing shareholders of JOL will receive 1 share of JIL (face value - Rs10/ sh) for every 20 shares of JOL (face value - Re1/sh). Post de-merger, JOL will be renamed at Jubilant Life Sciences which will continue with the existing business related to Pharma & Life Science (PLSPS) including the CRAMS, Generic Pharma & other businesses. For FY10, the APP business recorded revenues of Rs4.19b (11% of JOL's overall revenues) with EBITDA of Rs165m (2% of JOL's overall EBITDA) 11 November
4 We believe that Jubilant needs to focus on its core business of CRAMS. It currently has presence in CRAMS, Generics, Chemicals and Hospitals. We believe that the Generics business is unlikely to scale up significantly in the coming years given Jubilant's generic product pipeline. High debt, FCCB redemption remains an overhang Jubilant had raised US$310m in FCCBs in 2005/2006 to fund acquisitions and capex. Of these, FCCBs worth US$142m (US$202m incl YTM) are due for redemption in May We believe that these are unlikely to get converted into equity given the high conversion price of Rs413 (effective conversion price of Rs589 taking into account YTM). Cutting earnings estimates by 21% for FY11 and 15% for FY12 Based on the lower than expected 2QFY11 performance, we have cut our EBITDA estimates by 14% for FY11 and 7% for FY12. We have cut our EPS estimates for FY11E by 21% and for FY12E by 15.4%. We now forecast EPS of Rs20.3 for FY11 (23.4%YoY decline) and Rs24.4 for FY12 (up 20%YoY). Outlook and Valuation We believe that the proposed de-merger of the APP business is a positive step as it reflects management's intention to have a focused approach for the PLSPS business. The de-merger will also lead to a better RoCE for JOL as the APP business accounted for only 2% of JOL's FY10 EBITDA but 6% of capital employed. We believe Jubilant is well positioned to exploit the expected increase in outsourcing from India. Customer inventory de-stocking for CRAMS companies is coming to an end and we expect growth to rebound in FY11 as customers are likely to commence re-stocking. Over the past few years, Jubilant has made two large acquisitions in North America which has strengthened its presence in the sterile segment but has also resulted in a highly leveraged balance sheet. We also believe that some of the past acquisitions (like Draxis) have been made at expensive valuations resulting in extended payback periods. High debt, large FCCB redemption (US$202m in May-2011 including YTM) and low RoCE (8-12%) remain an overhang. Based on our revised estimates the stock is valued at 15.4x FY11E EPS and 12.8x FY12E EPS. Maintain Neutral. 11 November
5 : an investment profile Company description Limited is the largest specialty chemicals company in India with high degree of vertical integration along with global scale and reach in almost all its key products. Its business model thus spans pharmaceuticals & life sciences, industrial chemicals and performance chemicals. It has forayed into API business (by acquiring Max India's API operations) and into formulations and regulatory services (by acquiring PSI n.v and PSI supply).key investment arguments Key investment risks A composite and integrated player with offerings across the pharma and specialty chemicals value chain Continuous forward integration, with global scale capacities in key products and widespread global presence puts Jubilant on the high growth path. Growing share of the profitable Pharma business, driven by CRAMS, steriles & radiopharmaceuticals business, to ensure improved profitability and earnings visibility Recent developments Jubilant and Eli Lilly have extended Drug Discovery collaboration on successful delivery of Pre-clinical candidates. Valuation and view Slowdown in some of the CRAMS products, declining realizations and product rationalization (for the chemicals business) continues to impact Jubilant's topline growth. We expect an improvement in the CRAMS business only in FY12. The stock currently quotes at 15.4xFY11E and 12.8xFY12E EPS. We continue to believe that the stock price will continue to remain muted till clarity emerges on debt reduction and redemption of US$202m FCCBs (incl YTM). Maintain Neutral. Sector view The CRAMS segment is likely to witness exponential growth over the next few years. Comparative valuations Jubilant Divis Dishman P/E (x) FY11E FY12E P/BV (x) FY11E FY12E EV/Sales (x) FY11E FY12E EV/EBITDA (x) FY11E FY12E EPS: MOSL forecast v/s consensus (Rs) MOSL Consensus Variation Forecast Forecast (%) FY FY Target Price and Recommendation Current Target Upside Reco. Price (Rs) Price (Rs) (%) Neutral Stock performance (1 year) Shareholding Pattern (%) Sep-10 Jun-10 Sep-09 Promoter Domestic Inst Foreign Others Jubiliant Organosys (Rs) - LHS Rel. to Sensex (%) - RHS Nov-09 Feb-10 May-10 Aug-10 Nov November
6 Financials and Valuation 11 November
7 NOTES 11 November
8 For more copies or other information, contact Institutional: Navin Agarwal. Retail: Manish Shah Phone: (91-22) Fax: (91-22) Motilal Oswal Securities Ltd, 3rd Floor, Hoechst House, Nariman Point, Mumbai This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Motilal Oswal Securities Limited (hereinafter referred as MOSt) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon such. MOSt or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOSt or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. MOSt and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. To enhance transparency, MOSt has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. Disclosure of Interest Statement 1. Analyst ownership of the stock No 2. Group/Directors ownership of the stock No 3. Broking relationship with company covered No 4. Investment Banking relationship with company covered No This information is subject to change without any prior notice. MOSt reserves the right to make modifications and alternations to this statement as may be required from time to time. Nevertheless, MOSt is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries. 11 November
Hardick Bora
BSE Sensex S&P CNX 19,990 6,069 Bloomberg JOL IN Equity Shares (m) 159.3 M.Cap. (INR b)/(usd b) 26.0/0.5 52-Week Range (INR) 248/154 1,6,12 Rel. Perf. (%) -18/-28/-34 Financials & Valuation (INR b) Y/E
More informationReliance Communications
1QFY11 Results Update SECTOR: TELECOM Reliance Communications STOCK INFO. BSE Sensex: 18,167 S&P CNX: 5,452 BLOOMBERG RCOM IN REUTERS CODE RLCM.BO 13 August 2010 Previous Recommendation: Under Review Buy
More informationShriram Transport Finance
Results Update SECTOR: BANKING STOCK INFO. BSE Sensex: 18,113 S&P CNX: 5,442 BLOOMBERG SHTF IN REUTERS CODE SRTR.BO Equity Shares (m) 225.5 52-Week Range 651/291 1,6,12 Rel.Perf.(%) -1/12/71 M.Cap. (Rs
More informationMaruti Suzuki. CMP:Rs1,327 TP:Rs1,625 Buy
25 April 2011 4QFY11 Results Update Sector: Automobiles Maruti Suzuki BSE SENSEX S&P CNX 19,584 5,875 Bloomberg MSIL IN Diluted Equity Shares (m) 289.0 52-Week Range (Rs) 1,600/1,126 1,6,12 Rel.Perf.(%)
More informationDabur India. Neutral. Rs93
3QFY11 Results Update SECTOR: FMCG BSE SENSEX S&P CNX 18,022 5,417 Bloomberg DABUR IN Equity Shares (m) 1,738.0 52-Week Range (Rs) 112/79 1,6,12 Rel. Perf. (%) 5/-5/2 M.Cap. (Rs b) 160.8 M.Cap. (US$ b)
More informationGodrej Consumer Products
3QFY11 Results Update SECTOR: FMCG BSE SENSEX S&P CNX 19,151 5,743 Rs400 Godrej Consumer Products Neutral Bloomberg GCPL IN Equity Shares (m) 323.6 52-Week Range (Rs) 480/225 1,6,12 Rel. Perf. (%) 7/6/46
More informationPrevious Recommendation: Buy
2QCY10 Results Update SECTOR: CEMENT ACC STOCK INFO. BSE Sensex: 18,113 S&P CNX: 5,442 BLOOMBERG ACC IN REUTERS CODE ACC.BO Previous Recommendation: Buy Buy Rs816 Equity Shares (m) 187.9 52-Week Range
More informationPrevious Recommendation: Neutral QUARTERLY PERFORMANCE (INDIAN GAAP)
Results Update SECTOR: INFORMATION TECHNOLOGY Infosys Technologies STOCK INFO. BSE Sensex: 13,504 S&P CNX: 4,004 BLOOMBERG INFO IN REUTERS CODE INFY.BO Previous Recommendation: Neutral Neutral Rs1,727
More informationITC. Buy. Rs169. 3QFY11 Results Update 19,008 5,697
Results Update SECTOR: FMCG BSE SENSEX S&P CNX 19,8 5,697 Bloomberg ITC IN Equity Shares (m) 7,75.9 52-Week Range (Rs) 185/112 1,6,12 Rel. Perf. (%) 6/9/3 M.Cap. (Rs b) 1,31.5 M.Cap. (US$ b) 29.3 Rs169
More informationSanofi India. CMP: INR2,200 TP: INR1,848 Neutral
BSE SENSEX S&P CNX 16,846 5,110 Bloomberg SANL IN Equity Shares (m) 23.0 52-Week Range (INR) 2,430/1,980 1,6,12 Rel. Perf. (%) 3/-3/15 M.Cap. (INR b) 50.7 M.Cap. (USD b) 0.9 26 July 2012 2QCY12 Results
More informationStrides Arcolab. CMP: INR717 TP: INR829 Buy
BSE SENSEX S&P CNX 17,144 5,200 Bloomberg STR IN Equity Shares (m) 57.7 52-Week Range (INR) 794/276 1,6,12 Rel. Perf. (%) -2/37/98 M.Cap. (INR b) 41.4 M.Cap. (USD b) 0.7 31 July 2012 2QCY12 Results Update
More informationSun Pharmaceuticals. CMP: INR554 TP: INR614 Neutral
BSE SENSEX S&P CNX 17,849 5,416 Bloomberg SUNP IN Equity Shares (m) 1,035.6 52-Week Range (INR) 566/404 1,6,12 Rel. Perf. (%) -3/10/31 M.Cap. (INR b) 573.7 M.Cap. (USD b) 11.6 15 February 2012 3QFY12 Results
More informationPositive outlook for both JLR and domestic business. JLR's 1Q margins sustainable subject to stable forex; Buy
Update SECTOR: AUTOMOBILES BSE SENSEX S&P CNX 20,045 6,018 Rs1,070 Tata Motors Buy Bloomberg TTMT IN Reuters TAMO.BO Diluted Eq.Shares (m) 624.1 52-Week Range 1,089/520 1,6,12 Rel. Perf. (%) -4/30/58 M.Cap.
More informationAsian Paints. CMP: INR2,722 TP: INR3,161 Buy
BSE SENSEX S&P CNX 16,739 5,049 Bloomberg APNT IN Equity Shares (m) 95.9 52-Week Range (INR) 3,366/2,395 1,6,12 Rel. Perf. (%) -5/-3/14 M.Cap. (INR b) 261.1 M.Cap. (USD b) 4.9 23 January 2012 3QFY12 Results
More informationTitan Industries. CMP: INR222 TP: INR220 Neutral
BSE SENSEX S&P CNX 17,257 5,241 Bloomberg TTAN IN Equity Shares (m) 887.8 52-Week Range (INR) 255/154 1,6,12 Rel. Perf. (%) -1/13/3 M.Cap. (Rs b) 197.1 M.Cap. (US$ b) 3.6 2 August 2012 1QFY13 Results Update
More informationPidilite Industries. CMP: INR164 TP: INR186 Buy
BSE SENSEX S&P CNX 16,640 5,043 Bloomberg PIDI IN Equity Shares (m) 506.1 52-Week Range (INR) 188/134 1,6,12 Rel. Perf. (%) 1/20/5 M.Cap. (INR b) 83.0 M.Cap. (USD b) 1.5 27 July 2012 1QFY13 Results Update
More informationBGR Energy. Buy. Target price: Rs958. Large EPC order expected in FY11; order-book to double to Rs200b
BSE SENSEX S&P CNX 19,509 5,857 Target price: Rs958 Update SECTOR: ENGINEERING BGR Energy Buy Large EPC order expected in FY11; order-book to double to Rs200b Bloomberg BGRL IN Reuters BGRE.BO Equity Shares
More informationLarsen & Toubro. CMP: INR1,160 TP: INR1,417 Buy
BSE SENSEX S&P CNX 16,216 4,908 Bloomberg LT IN Equity Shares (m) 608.9 52-Week Range (INR) 1,868/971 1,6,12 Rel. Perf. (%) -4/-7/12 M.Cap. (INR b) 706.3 M.Cap. (USD b) 13.1 * Consolidated; EPS is fully
More informationJubilant Foodworks. CMP: INR1,189 TP: INR1,0541,054 Neutral
BSE SENSEX S&P CNX 16,846 5,110 Bloomberg JUBI IN Equity Shares (m) 63.5 52-Week Range (INR) 1,189/633 1,6,12 Rel. Perf. (%) 4/38/47 M.Cap. (INR b) 75.5 M.Cap. (USD b) 1.3 26 July 2012 1QFY13 Results Update
More informationNTPC CMP: INR169 TP: INR191 Buy
BSE SENSEX S&P CNX 18,625 5,664 Bloomberg NTPC IN Equity Shares (m) 8,245.5 52-Week Range (INR) 190/139 1,6,12 Rel. Perf. (%) 3/-4/-11 M.Cap. (INR b) 1,393.5 M.Cap. (USD b) 26.0 26 October 2012 2QFY13
More informationCMP: INR121 TP: INR193 Buy
BSE SENSEX S&P CNX 17,085 5,139 20 October 2011 2QFY12 Results Update Sector: Metals Hindustan Zinc CMP: INR121 TP: INR193 Buy Bloomberg HZ IN Equity Shares (m) 4,225.3 52-Week Range (INR) 155/109 1,6,12
More informationCummins India. CMP: INR430 TP: INR462 Neutral
BSE SENSEX S&P CNX 16,070 4,870 Bloomberg KKC IN Equity Shares (m) 277.2 52-Week Range (INR) 515/322 1,6,12 Rel. Perf. (%) -3/30/-4 M.Cap. (INR b) 119.2 M.Cap. (USD b) 2.2 17 May 2012 4QFY12 Results Update
More informationJubilant Foodworks. CMP: INR1,051 TP: INR1,054 Neutral
BSE SENSEX S&P CNX 16,420 4,966 Bloomberg JUBI IN Equity Shares (m) 63.5 52-Week Range (INR) 1,144/536 1,6,12 Rel. Perf. (%) -6/37/53 M.Cap. (INR b) 66.7 M.Cap. (USD b) 1.3 11 May 2012 4QFY12 Results Update
More informationUnitech. CMP: INR20 TP: INR30 Buy
BSE SENSEX S&P CNX 16,328 4,943 Bloomberg UT IN Equity Shares (m) 2,438.8 52-Week Range (INR) 38/17 1,6,12 Rel. Perf. (%) -25/-14/-34 M.Cap. (INR b) 48.8 M.Cap. (USD b) 0.9 16 May 2012 4QFY12 Results Update
More informationJaiprakash Associates
BSE SENSEX S&P CNX 16,312 4,951 Bloomberg JPA IN Equity Shares (m) 2,126.5 52-Week Range (INR) 89/50 1,6,12 Rel. Perf. (%) -14/-4/-17 M.Cap. (INR b) 127.9 M.Cap. (USD b) 2.3 31 May 2012 4QFY12 Results
More informationDabur India. CMP: INR106 TP: INR94 Neutral
28 July 2011 1QFY12 Results Update Sector: FMCG BSE SENSEX S&P CNX 18,210 5,488 Dabur India CMP: INR106 TP: INR94 Neutral Bloomberg DABUR IN Equity Shares (m) 1,740.0 52-Week Range (INR) 122/87 1,6,12
More informationBGR Energy. CMP: INR284 TP: INR296 Neutral
BSE SENSEX S&P CNX 16,312 4,951 Bloomberg BGRL IN Equity Shares (m) 72.0 52-Week Range (INR) 512/173 1,6,12 Rel. Perf. (%) -8/8/-31 M.Cap. (INR b) 20.5 M.Cap. (USD b) 0.4 31 May 2012 4QFY12 Results Update
More informationMedium term profitability driven by commodity earnings
Update SECTOR: UTILITIES BSE SENSEX S&P CNX 18,180 5,462 Bloomberg SHAREHOLDING PATTERN % (JUN-10) Others, 16.8 Foreign, 21.8 STOCK PERFORMANCE (1 YEAR) TPWR IN Promoter 31.9 Domestic Inst, 29.5 Rs1,255
More informationSanjay Jain Pavas Pethia
BSE Sensex S&P CNX 19,561 5,923 Bloomberg SAIL IN Equity Shares (m) 4,130.4 M.Cap. (INR b)/(usd b) 334.6/6.2 52-Week Range (INR) 116/76 1,6,12 Rel. Perf. (%) -11/-17/-38 Financials & Valuation (INR b)
More informationReliance Infrastructure CMP: INR528
BSE SENSEX S&P CNX 17,657 5,363 16 August 2012 1QFY13 Results Update Sector: Utilities Reliance Infrastructure CMP: INR528 Buy Bloomberg RELI IN Equity Shares (m) 267.5 52-Week Range (INR) 680/328 1,6,12
More informationBGR Energy. CMP: INR282 TP: INR253 Neutral
BSE SENSEX S&P CNX 17,413 5,283 Bloomberg BGRL IN Equity Shares (m) 72.0 52-Week Range (INR) 378/173 1,6,12 Rel. Perf. (%) -9/17/-22 M.Cap. (INR b) 20.3 M.Cap. (USD b) 0.4 6 August 2012 1QFY13 Results
More informationLarsen & Toubro. CMP: INR1,278 TP: INR1,380 Buy
BSE SENSEX S&P CNX 16,786 5,050 Bloomberg LT IN Equity Shares (m) 608.9 52-Week Range (INR) 1,933/971 1,6,12 Rel. Perf. (%) 20/-19/-11 M.Cap. (INR b) 778.1 M.Cap. (USD b) 15.5 * Consolidated; EPS is fully
More informationCummins India. Buy. Rs698. Encouraging long-term outlook, as parent looks at sourcing more from India; domestic sales to grow at a steady pace
Update SECTOR: ENGINEERING BSE SENSEX S&P CNX 18,180 5,462 Bloomberg SHAREHOLDING PATTERN % (JUN-10) Foreign, 11.8 Domestic Inst, 21.0 Others, 16.2 STOCK PERFORMANCE (1 YEAR) KKC IN Promoter 51.0 Rs698
More informationCanara Bank. CMP: INR419 TP: INR525 Buy
BSE SENSEX S&P CNX 18,817 5,724 Bloomberg CBK IN Equity Shares (m) 443.0 52-Week Range (INR) 566/349 1,6, 12 Rel.Perf.(%) -7/-18/-17 M.Cap. (INR b) 170.3 M.Cap. (USD b) 3.0 7 November 2012 2QFY13 Results
More informationHardick Bora 4QCY12 Results Update Sector: Healthcare Sanofi India CMP: INR2,307 TP: INR2,015 Neutral
BSE Sensex S&P CNX 19,332 5,855 Bloomberg SANL IN Equity Shares (m) 23.0 M.Cap. (INR b)/(usd b) 53.1/1.0 52-Week Range (INR) 2,450/2,002 1,6,12 Rel. Perf. (%) 9/-1/-4 Financials & Valuation (INR b) Y/E
More informationPunjab National Bank. CMP:INR1,103 TP:INR1,500 Buy
BSE SENSEX S&P CNX 18,210 5,488 28 July 2011 1QFY12 Results Update Sector: Banking Punjab National Bank CMP:INR1,103 TP:INR1,500 Buy Bloomberg PNB IN Equity Shares (m) 316.8 52-Week Range (INR) 1,395/971
More informationBGR Energy. CMP: INR266 TP: INR230 Neutral
BSE SENSEX S&P CNX 18,562 5,645 Bloomberg BGRL IN Equity Shares (m) 72.0 52-Week Range (INR) 374/173 1,6,12 Rel. Perf. (%) -3/27/-24 M.Cap. (INR b) 19.2 M.Cap. (USD b) 0.4 3 November 2012 2QFY13 Results
More informationGodrej Consumer Products
BSE SENSEX S&P CNX 17,602 5,337 Bloomberg GCPL IN Equity Shares (m) 340.3 52-Week Range (INR) 658/370 1,6,12 Rel. Perf. (%) 5/37/42 M.Cap. (INR b) 205.9 M.Cap. (USD b) 3.7 7 August 2012 1QFY13 Results
More informationHindustan Unilever. CMP:INR324 TP:INR302 Neutral
BSE SENSEX S&P CNX 18,197 5,482 29 July 2011 1QFY12 Results Update Sector: FMCG Hindustan Unilever CMP:INR324 TP:INR302 Neutral Bloomberg HUVR IN Equity Shares (m) 2,159.5 52-Week Range (INR) 347/250 1,6,12
More informationGodawari Power & Ispat
BSE SENSEX S&P CNX CMP: INR103 TP: INR185 Buy 17,077 5,158 Bloomberg GODPI IN Equity Shares (m) 31.8 52-Week Range (INR) 200/70 1,6,12 Rel. Perf. (%) 32/-31/-33 M.Cap. (INR b) 3.3 M.Cap. (USD m) 65.3 Consolidated
More informationIdea Cellular. CMP: INR81 TP: INR Under Review
BSE SENSEX S&P CNX 16,918 5,128 Bloomberg IDEA IN Equity Shares (m) 3,308.8 52-Week Range (INR) 104/71 1,6,12 Rel. Perf. (%) 6/-13/4 M.Cap. (INR b) 268.0 M.Cap. (USD b) 4.8 25 July 2012 1QFY13 Results
More informationIDBI Bank. CMP: INR106 TP: INR121 Neutral
BSE SENSEX S&P CNX 17,207 5,223 Bloomberg IDBI IN Equity Shares (m) 1,278.4 52-Week Range (INR) 154/77 1,6,12 Rel.Perf.(%) -1/0/-7 M.Cap. (INR b) 135.5 M.Cap. (USD b) 2.6 24 April 2012 4QFY12 Results Update
More informationAddressing key investor concerns. Dec-09
22 March 2011 Update Sector: IT BSE SENSEX S&P CNX 17,988 5,414 Rs452 HCL Technologies Buy Bloomberg HCLT IN Equity Shares (m) 692.1 52-Week Range (Rs) 518/338 1,6,12 Rel. Perf. (%) 0/17/19 M.Cap. (Rs
More informationIndusInd Bank. CMP: INR345 TP: INR419 Buy
BSE SENSEX S&P CNX 17,504 5,332 Bloomberg IIB IN Equity Shares (m) 467.7 52-Week Range (INR) 352/222 1,6,12 Rel.Perf.(%) 13/25/34 M.Cap. (INR b) 161.4 M.Cap. (USD b) 3.1 20 April 2012 4QFY12 Results Update
More informationGAIL India NEUTRAL. Performance Highlights CMP. `363 Target Price - 2QFY2013 Result Update Oil & Gas. Investment Period -
2QFY2013 Result Update Oil & Gas October 26, 2012 GAIL India Performance Highlights Quarterly highlights (Standalone) Y/E March (` cr) 2QFY2013 2QFY2012 % chg (yoy) 1QFY2013 % chg (qoq) Net sales 11,361
More informationNiket Shah
BSE Sensex S&P CNX 20,213 6,147 Bloomberg VGRD IN Equity Shares (m) 29.8 M.Cap. (INR b)/(usd b) 14.6/0.3 52-Week Range (INR) 591/180 1,6,12 Rel. Perf. (%) -8/-6/138 Financial summary (INR b) Y/E March
More informationIndiabulls Real Estate
BSE SENSEX S&P CNX 19,136 5,750 Bloomberg IBREL IN Equity Shares (m) 402.2 52-Week Range 219/99 1,6,12 Rel. Perf. (%) 2/-32/-37 M.Cap. (Rs b) 50.3 M.Cap. (USD b) 1.1 30 April 2011 4QFY11 Results Update
More informationCanara Bank. CMP: INR464 TP: INR645 Buy
BSE SENSEX S&P CNX 17,234 5,205 Bloomberg CBK IN Equity Shares (m) 443.0 52-Week Range (INR) 672/349 1,6, 12 Rel.Perf.(%) 22/2/-13 M.Cap. (INR b) 205.6 M.Cap. (USD b) 4.1 31 January 2012 3QFY12 Results
More informationTata Power. CMP: INR111 TP: INR92 Neutral
BSE SENSEX S&P CNX 17,749 5,382 Bloomberg TPWR IN Equity Shares (m) 2,373.3 52-Week Range (INR) 135/81 1,6,12 Rel. Perf. (%) 10/-5/-10 M.Cap. (INR b) 263.9 M.Cap. (USD b) 5.3 13 February 2012 3QFY12 Results
More informationSiddharth Bothra
BSE Sensex S&P CNX 19,152 5,797 Bloomberg CSTRL IN Equity Shares (m) 494.6 M.Cap. (INR b)/(usd b) 158/2.9 52-Week Range (INR) 338/223 1,6,12 Rel. Perf. (%) 12/-3/26 Financials & Valuation (INR b) Y/E March
More informationPantaloon Retail. CMP: INR177 TP: INR192 Neutral
BSE SENSEX S&P CNX 17,773 5,390 Bloomberg PF IN Equity Shares (m) 217.1 52-Week Range (INR) 364/125 1,6,12 Rel. Perf. (%) 9/-49/-29 M.Cap. (Rs b) 38.4 M.Cap. (US$ b) 0.8 14 February 2012 2QFY12 Results
More informationSteel Authority of India
BSE SENSEX S&P CNX 16,439 4,990 4QFY12 Results Update Sector: Metals Steel Authority of India CMP: INR93 TP: INR99 Sell Bloomberg SAIL IN Equity Shares (m) 4,130.4 52-Week Range (INR) 151/73 1,6,12 Rel.
More informationCMP: INR350 TP: INR375 Downgrade to Neutral
BSE Sensex S&P CNX 19,497 5,897 Bloomberg COAL IN Equity Shares (m) 6,316.4 M.Cap. (INR b)/(usd b) 2,211/41 52-Week Range (INR) 386/301 1,6,12 Rel. Perf. (%) 1/-11/-5 Financials & Valuation (INR b) Y/E
More informationAmber Enterprises India Ltd
3QFY2019 Result Update Consumer Durable February 16, 2019 Amber Enterprises India Ltd Performance Update (` cr) 3QFY19 3QFY18 % yoy 2QFY19 % qoq Revenue 388.8 338.4 14.9 226.3 71.8 EBITDA 22.1 24.1 (8.2)
More informationShree Renuka Sugars. CMP: INR26 TP: INR45 Buy
BSE SENSEX S&P CNX 16,219 4,924 1 June 2012 6QSY12 Results Update Sector: Sugar CMP: INR26 TP: INR45 Buy Bloomberg SHRS IN Equity Shares (m) 671.0 52-Week Range (INR) 76/23 1,6,12 Rel. Perf. (%) -10/-16/-45
More informationCoal India CMP: INR348 TP: INR408 Buy
BSE SENSEX S&P CNX 17,633 5,348 Bloomberg COAL IN Equity Shares (m) 6,316.4 52-Week Range (INR) 404/294 1,6,12 Rel. Perf. (%) -4/4/-15 M.Cap. (INR b) 2,198.1 M.Cap. (USD b) 39.7 14 August 2012 1QFY13 Results
More informationPetronet LNG. CMP: INR146 TP: INR205 Buy
BSE SENSEX S&P CNX 17,236 5,229 Bloomberg PLNG IN Equity Shares (m) 750.0 52-Week Range (INR) 186/122 1,6,12 Rel. Perf. (%) 3/-11/-10 M.Cap. (INR b) 109.7 M.Cap. (USD b) 2.0 1 August 2012 1QFY13 Results
More informationGodrej Consumer Products
BSE SENSEX S&P CNX 18,755 5,698 Bloomberg GCPL IN Equity Shares (m) 340.3 52-Week Range (INR) 745/370 1,6,12 Rel. Perf. (%) 4/17/67 M.Cap. (INR b) 246.4 M.Cap. (USD b) 4.6 5 November 2012 2QFY13 Results
More informationHardick Bora 4QFY13 Results Update Sector: Healthcare Dr Reddy's Laboratories CMP: INR2,026 TP: INR2,375 Buy
BSE Sensex S&P CNX 19,772 5,995 Bloomberg DRRD IN Equity Shares (m) 169.2 M.Cap. (INR b)/(usd b) 344/6.3 52-Week Range (INR) 2,151/1,528 1,6,12 Rel. Perf. (%) -2/9/0 Financials & Valuation (INR b) Y/E
More informationHindalco. CMP: INR113 TP: INR151 Buy
BSE SENSEX S&P CNX 18,817 5,724 Bloomberg HNDL IN Equity Shares (m) 1,990.0 52-Week Range (INR) 165/100 1,6,12 Rel. Perf. (%) -9/-18/-26 M.Cap. (INR b) 224.9 M.Cap. (USD b) 4.1 Consolidated 2QFY13 Results
More informationAxis Bank. CMP: INR1,008 TP: INR1,240 Buy
BSE SENSEX S&P CNX 16,739 5,049 Bloomberg AXSB IN Equity Shares (m) 410.5 52-Week Range 1,461/785 1,6,12 Rel.Perf.(%) 11/-9/-9 M.Cap. (INR b) 413.8 M.Cap. (USD b) 8.2 20 January 2012 Results Update Sector:
More informationHardick Bora QFY13 Results Update Sector: Healthcare Lupin CMP: INR725 TP: INR851 Buy
BSE Sensex S&P CNX 19,990 6,069 Bloomberg LPC IN Equity Shares (m) 447.6 M.Cap. (INR b)/(usd b) 324.5/6.0 52-Week Range (INR) 739/507 1,6,12 Rel. Perf. (%) 9/18/13 Financials & Valuation (INR b) Y/E March
More informationBHEL. CMP: INR227 TP: INR233 Neutral
BSE SENSEX S&P CNX 18,636 5,666 Bloomberg BHEL IN Equity Shares (m) 2,447.6 52-Week Range (INR) 368/198 1,6,12 Rel. Perf. (%) -7/-7/-35 M.Cap. (INR b) 556.2 M.Cap. (USD b) 10.3 30 October 2012 2QFY13 Results
More informationGodrej Properties. CMP: INR595 TP: INR635 Neutral
BSE SENSEX S&P CNX 16,913 5,114 Bloomberg GPL IN Equity Shares (m) 78.0 52-Week Range 845/570 1,6,12 Rel. Perf. (%) 0/-9/-2 M.Cap. (INR b) 46.4 M.Cap. (USD b) 0.9 4QFY12 Results Update Sector: Real Estate
More informationKotak Mahindra Bank. CMP: INR495 TP: INR429 Neutral
BSE SENSEX S&P CNX 16,739 5,049 Bloomberg KMB IN Equity Shares (m) 689.3 52-Week Range 515/333 1,6,12 Rel.Perf.(%) 0/12/31 M.Cap. (Rs b) 340.5 M.Cap. (US$ b) 6.7 25 January 2012 3QFY12 Results Update Sector:
More informationThermax. CMP: INR522 TP: INR414 Neutral
BSE SENSEX S&P CNX 17,605 5,326 Bloomberg TMX IN Equity Shares (m) 119.2 52-Week Range (INR) 720/388 1,6,12 Rel. Perf. (%) 14/1/-21 M.Cap. (INR b) 60.3 M.Cap. (USD b) 1.1 3 February 2012 3QFY12 Results
More informationIdea Cellular. CMP: INR159 TP: INR200 Buy
BSE SENSEX S&P CNX 19,164 5,678 Bloomberg IDEA IN Equity Shares (m) 3,316.2 M.Cap. (INR b) / (USD b) 513.7/8.4 52-Week Range (INR) 176/72 1, 6, 12 Rel. Per (%) 12/45/83 Financials & Valuation (INR Billion)
More informationSohail Halai Alpesh Mehta
BSE Sensex S&P CNX 20,039 6,064 Bloomberg IDBI IN Equity Shares (m) 1,278.4 M.Cap. (INR b)/(usd b) 144.9/2.7 52-Week Range (INR) 122/82 1,6,12 Rel.Perf.(%) -1/6/2 Financials & Valuation (INR b) Y/E March
More informationOberoi Realty. CMP: INR264 TP: INR315 Buy
BSE SENSEX S&P CNX 17,151 5,202 Bloomberg OBER IN Equity Shares (m) 328.2 52-Week Range (INR) 323/205 1,6,12 Rel. Perf. (%) 4/15/16 M.Cap. (INR b) 87.0 M.Cap. (USD b) 1.7 26 April 2012 4QFY12 Results Update
More informationDabur India. CMP: INR130 TP: INR135 Neutral
BSE SENSEX S&P CNX 18,625 5,664 29 October 2012 2QFY13 Results Update Sector: Consumer Dabur India CMP: INR130 TP: INR135 Neutral Bloomberg DABUR IN Equity Shares (m) 1,740.7 52-Week Range (Rs) 139/92
More informationPunjab National Bank. CMP: INR716 TP: INR950 Buy
BSE SENSEX S&P CNX 16,839 5,100 Bloomberg PNB IN Equity Shares (m) 339.2 52-Week Range (INR) 1,144/703 1,6,12 Rel.Perf.(%) -8/-24/-28 M.Cap. (INR b) 242.8 M.Cap. (USD b) 4.4 30 July 2012 1QFY13 Results
More informationMonnet Ispat. CMP: INR449 TP: INR518 Neutral
4QFY12 Results Update Sector: Metals Monnet Ispat BSE SENSEX S&P CNX 16,328 4,943 CMP: INR449 TP: INR518 Neutral Bloomberg MISP IN Equity Shares (m) 64.4 52-Week Range (INR) 561/305 1,6,12 Rel. Perf. (%)
More informationSUN TV Network NEUTRAL. Performance Highlights CMP. `297 Target Price - 1QFY2013 Result Update Media. Investment Period -
1QFY2013 Result Update Media August 8, 2012 SUN TV Network Performance Highlights Quarterly data (Standalone) (` cr) 1QFY13 1QFY12 % yoy 4QFY12 %qoq Revenue 426 454 (6.2) 427 (0.3) EBITDA 323 366 (11.7)
More informationCMP: INR401 TP: INR516 Buy. * After ESOP charges; # Axon consolidated in December 2008
19 October 2011 1QFY12 Results Update Sector: Technology BSE SENSEX S&P CNX 16,748 5,038 Bloomberg HCLT IN Equity Shares (m) 700.9 52-Week Range (INR) 528/360 1,6,12 Rel. Perf. (%) 4/-1/7 M.Cap. (INR b)
More informationPunjab National Bank. CMP: INR768 TP: INR963 Buy
BSE SENSEX S&P CNX 16,480 4,975 Bloomberg PNB IN Equity Shares (m) 339.2 52-Week Range (INR) 1,200/751 1,6,12 Rel.Perf.(%) -12/-16/-18 M.Cap. (INR b) 260.5 M.Cap. (USD b) 4.8 10 May 2012 4QFY12 Results
More informationSandipan Pal QFY13 Results Update Sector: Real Estate Unitech CMP: INR29 TP: INR44 Buy
BSE Sensex S&P CNX 19,608 5,933 Bloomberg UT IN Equity Shares (m) 2,438.8 M.Cap. (INR b)/(usd b) 70/1.3 52-Week Range (INR) 41/18 1,6,12 Rel. Perf. (%) -27/24/-13 Financials & Valuation (INR b) Y/E March
More informationITC. CMP: INR201 TP: INR230 Buy
BSE SENSEX S&P CNX 16,739 5,049 Bloomberg ITC IN Equity Shares (m) 7,738.1 52-Week Range (INR) 211/149 1,6,12 Rel. Perf. (%) 3/23/38 M.Cap. (INR b) 1,601.0 M.Cap. (USD b) 32.1 21 January 2012 Results Update
More informationOberoi Realty. CMP: INR269 TP: INR320 Buy
BSE SENSEX S&P CNX 18,682 5,684 Bloomberg OBER IN Equity Shares (m) 328.2 52-Week Range (INR) 323/205 1,6,12 Rel. Perf. (%) 13/-7/7 M.Cap. (INR b) 88.3 M.Cap. (USD b) 1.6 22 October 2012 2QFY13 Results
More informationJinesh Gandhi Chirag Jain
BSE Sensex S&P CNX 19,561 5,923 Bloomberg EIM IN Equity Shares (m) 27.0 M.Cap. (INR b)/(usd b) 72.0/1.3 52-Week Range 3,240/1,620 1,6,12 Rel. Perf. (%) -4/17/40 Financials & Valuation (INR b) Y/E Dec 2013E
More informationColgate-Palmolive (India)
Result Update Colgate-Palmolive (India) 27 July 218 Reuters: COLG.BO; Bloomberg: CLGT IN Tough Times Continue Colgate-Palmolive (India) or CLGT reported a mixed earnings performance in. Volume and revenue
More informationCentury Plyboards Ltd
May-15 Aug-15 Nov-15 Feb-16 May-16 Aug-16 Nov-16 Feb-17 May-17 Aug-17 Nov-17 Feb-18 4QFY2018 Result Update Plywood May 19, 2018 Century Plyboards Ltd Performance Update (Rs cr) 4QFY18 4QFY17 % yoy 3QFY17
More informationAlembic BUY. Performance Highlights. Target Price. 1QFY2011 Result Update Pharmaceutical. Investment Period 12 months
1QFY2011 Result Update Pharmaceutical August 2, 2010 Alembic Performance Highlights Y/E March (Rs cr) 1QFY2011 4QFY2010 % chg (qoq) 1QFY2010 % chg (yoy) Net Sales 279 267 4.6 291 (4.0) Other Income 1 1
More informationPunjab National Bank. CMP: INR940 TP: INR1,275 Buy
BSE SENSEX S&P CNX 17,194 5,199 Bloomberg PNB IN Equity Shares (m) 316.8 52-Week Range (INR) 1,234/751 1,6,12 Rel.Perf.(%) 9/-10/-9 M.Cap. (INR b) 297.7 M.Cap. (USD b) 6.0 1 February 2012 3QFY12 Results
More informationCadila Healthcare NEUTRAL. Performance Highlights CMP. `495 Target Price - 4QFY2017 Result Update Pharmaceutical.
Feb-14 May-14 Aug-14 Nov-14 Feb-15 May-15 Aug-15 Nov-15 Feb-16 May-16 Aug-16 Nov-16 Feb-17 May-17 4QFY2017 Result Update Pharmaceutical June 5, 2017 Cadila Healthcare Performance Highlights Y/E March (`
More informationSun Pharma NEUTRAL. Performance Highlights CMP. 1QFY2013 Result Update Pharmaceutical. `676 Target Price - Investment Period -
1QFY2013 Result Update Pharmaceutical August 10, 2012 Sun Pharma Performance Highlights (` cr) 1QFY2013 4QFY2012 % chg qoq 1QFY2012 % chg yoy Net sales 2,658 2,330 14.1 1,636 62.5 Other income (2) 218-110
More informationJinesh Gandhi Sandipan Pal
BSE Sensex S&P CNX 20,224 6,157 Bloomberg BCORP IN Equity Shares (m) 77.0 M.Cap. (INR b)/(usd b) 20.5/0.4 52-Week Range (INR) 342/202 1,6,12 Rel. Perf. (%) 6/-15/-23 Financials & Valuation (INR b) Y/E
More informationRallis India NEUTRAL. Performance Highlights CMP. `237 Target Price - 1QFY2018 Result Update Agrichemical. Investment Period - 3-year price chart
Jan-12 Jul-12 Jan-13 Jul-13 Jan-14 Jul-14 Jan-15 Jul-15 Jan-16 Jul-16 Jan-17 1QFY2018 Result Update Agrichemical July 26, 2017 Rallis India Performance Highlights Y/E March (` cr) 1QFY2018 4QFY2017 % chg
More informationTorrent Pharmaceuticals
BSE SENSEX S&P CNX 21,338 6,339 Bloomberg TRP IN Equity Shares (m) 169.2 M.Cap. (INR b) / (USD b) 80.4/1.3 52-Week Range (INR) 535/324 1, 6, 12 Rel.Per (%) 4/12/32 Financials & Valuation (INR Million)
More informationGMM Pfaudler Limited BUY. Performance Update CMP. `945 Target Price ` QFY2019 Result Update Industrial Machinery. Investment Period 12 Months
2QFY2019 Result Update Industrial Machinery October 26, 2018 GMM Pfaudler Limited Performance Update Standalone (` cr) Q2FY19 Q2FY18 % yoy Q1FY19 % qoq Net sales 99.2 93.2 29.8% 76.4 6.4% EBITDA 16.0 15.3
More informationInox Wind BUY. Performance Highlights. CMP Target Price `242 `286. 4QFY2016 Result Update Capital Goods. 3 year price chart
4QFY216 Result Update Capital Goods May 11, 216 Inox Wind Performance Highlights Quarterly Data (Consolidated) ( ` cr) 4QFY16 4QFY15 % chg (yoy) 3QFY16 % chg (qoq) Total Income 1,829 93 96.6 941 94.2 EBITDA
More informationHero MotoCorp NEUTRAL. Performance Highlights. CMP `2,245 Target Price - 4QFY2012 Result Update Automobile. Investment Period - Key financials
4QFY212 Result Update Automobile Hero MotoCorp Performance Highlights Y/E March (` cr) 4QFY12 4QFY11 % chg (yoy) Angel est. % diff NEUTRAL CMP `2,245 Target Price - Investment Period - Net sales 6,35 5,391
More informationRallis India SELL. Performance Highlights. `231 Target Price 189 CMP. 2QFY2018 Result Update Agrichemical. Investment Period 12 months
Jan-12 Jun-12 Nov-12 Apr-13 Sep-13 Feb-14 Jul-14 Dec-14 May-15 Oct-15 Mar-16 Aug-16 Jan-17 Jun-17 Nov-17 2QFY2018 Result Update Agrichemical November 21, 2017 Rallis India Performance Highlights Y/E March
More informationCross service charges at INR m/quarter
BSE SENSEX S&P CNX 19,636 5,940 Cummins India CMP: INR504 TP: INR585 Buy LHP products to be an important growth driver Cross service charges at INR100-200m/quarter 20 February 2013 Update Sector: Capital
More informationTVS Motor Company BUY. Performance Highlights. CMP Target Price `39 `45. 2QFY2013 Result Update Automobile. Quarterly highlights (Standalone)
2QFY2013 Result Update Automobile November 1, 2012 TVS Motor Company Performance Highlights Quarterly highlights (Standalone) Y/E March (` cr) 2QFY13 2QFY12 % chg (yoy) 1QFY13 % chg (qoq) Net Sales 1,691
More informationBlue Star Ltd BUY. Performance Update. CMP Target Price `703 `867. 1QFY2019 Result Update Cons. Durable. 3-year price chart.
Aug-15 Oct-15 Dec-15 Feb-16 Apr-16 Jun-16 Aug-16 Oct-16 Dec-16 Jan-17 Apr-17 May-17 Jul-17 Sep-17 Nov-17 Jan-18 Mar-18 May-18 Jul-18 1QFY2019 Result Update Cons. Durable August 10, 2018 Blue Star Ltd Performance
More informationShree Renuka Sugars. CMP: INR41 TP: INR50 Buy
BSE SENSEX S&P CNX 18,202 5,532 Bloomberg SHRS IN Equity Shares (m) 671.0 52-Week Range (INR) 87/23 1,6,12 Rel. Perf. (%) 14/-39/-51 M.Cap. (INR b) 27.3 M.Cap. (USD b) 0.6 16 February 2012 5QSY12 Results
More informationMarket share recovery, price hike, content leverage to drive growth
BSE Sensex S&P CNX 24,377 7,276 Stock Info Bloomberg DITV IN Equity Shares (m) 1,064.8 52-Week Range (INR) 71/40 1, 6, 12 Rel. Per (%) 6/-15/-41 M.Cap. (INR b) 58.2 M.Cap. (USD b) 1.0 Financial Snapshot
More informationGraphite India BUY. Performance Highlights CMP. `93 Target Price `124. 4QFY2012 Result Update Capital Goods. Investment Period 12 Months
4QFY2012 Result Update Capital Goods May 11, 2012 Graphite India Performance Highlights Y/E March (` cr) 4QFY2012 3QFY2012 % chg (qoq) 4QFY2011 % chg (yoy) Net sales 452 437 3.5 304 48.6 EBITDA 83 90 (7.7)
More informationJaypee Infratech. CMP: INR33 TP: INR45 Buy
BSE SENSEX S&P CNX 2,550,318 Bloomberg JPIN IN Equity Shares (m) 1,388.9 M.Cap. (INR b) / (USD b) 51.3/0.9 52-Week Range (INR) 2/1 1,, 12 Rel. Per (%) 1/9/-3 Financials & Valuation (INR m) Y/E Mar 201
More informationDr. Reddy s Laboratories
2QFY2017 Result Update Pharmaceutical November 7, 2016 Dr. Reddy s Laboratories Performance Highlights Y/E March (` cr) 2QFY2017 1QFY2017 % chg (qoq) 2QFY2016 % chg (yoy) Net sales 3,586 3,235 10.9 3,989
More information